BioAge Labs Inc. BIOA 深 沪
已收盘 10-24 16:00:00 美东时间
7.60
-0.350
-4.40%
华盛通- 最 高8.05
- 今 开8.00
- 成交量 77.12万股
- 最 低 7.33
- 昨 收 7.95
- 总市值 2.72亿
- 52周最高 23.85
- 市盈率 静 --
- 换手率 2.15%
- 52周最低 2.88
- 委 比 -58.54%
- 总股本 3585.00万
- 历史最高 26.62
- 量 比 0.47
- 振 幅 9.06%
- 历史最低 0.156
- 每 手 1
- 风险率 5.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | VTYX大涨71%！新药研究取得积极结果；SEV转型为公益公司，涨近58%
VTYX大涨71%！新药在肥胖和心血管风险因素患者中的2期研究取得积极结果；SEV转型为公益公司，涨近58%>>
10-24 15:16
美股牛股 | ARMP大涨超103%！抗血感染药物在中期试验中显示出积极结果；直觉外科公司涨近14%
ARMP大涨超103%！抗血感染药物在中期试验中显示出积极结果；直觉外科公司涨近14%，Q3业绩表现优异，远超市场预期>>
10-23 14:51
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
Citigroup Upgrades Bioage Labs to Buy, Raises Price Target to $10
Citigroup analyst Samantha Semenkow upgrades Bioage Labs (NASDAQ:BIOA) from Neutral to Buy and raises the price target from $5 to $10.
10-22 19:21
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025
STOCKHOLM, Oct. 14, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanem...
10-14 13:14
BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile
BioCryst Pharmaceuticals has agreed to acquire Astria Therapeutics for approximately $700 million in enterprise value, with the aim of adding Astria's Phase 3 HAE drug candidate, navenibart, to its portfolio. The deal is expected to solidify double-digit growth for BioCryst's HAE division over the next decade and maintain profitability. Navenibart is a long-acting, injectable therapy with a differentiated dosing schedule, addressing unmet needs i...
10-14 11:00
Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
Biomerica Inc. appoints Gary Huff as an independent board member, leveraging his extensive experience in diagnostics, healthcare, and leadership. Huff, former CEO of LabCorp Diagnostics, brings a proven track record of commercial success and strategic vision. Biomerica highlights his ability to drive growth and innovation, particularly in advancing its inFoods® IBS product, a diagnostic-guided therapy for irritable bowel syndrome showing promisin...
10-08 12:19
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
STOCKHOLM, Oct. 6, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: Leqembi Iq...
10-07 06:02
BioArctic’s Leqembi Iqlik Launches in U.S. for Alzheimer’s Maintenance
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an announcement. BioArctic AB’...
10-07 05:04
BioAge Labs files $250M mixed securities shelf
BioAge Labs (NASDAQ:BIOA) files $250M mixed securities shelf. This prospectus is not an offer to sell these securities. Filing More on Powell Industries: From Backlog Boom To Growth Bust Polygon Stead...
10-03 04:42
